Trial Profile

A phase 1 randomized, double-blind, placebo-controlled first-in-human trial to assess the safety, tolerability, and pharmacokinetics of AIC468 in healthy volunteers

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 21 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AIC 468 (Primary) ; AIC 468 (Primary)
Indications Polyomavirus infections
Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use

Most Recent Events

20 Oct 2025 Results presented in a AiCuris media release
20 Oct 2025 According to AiCuris media release, new clinical data from this presented at the 2025 ID Week Annual Meeting, taking place October 19-22 in Atlanta, Georgia.
16 Sep 2025 According to AiCuris media release, data from this trial will be presented at the 2025 ID Week Annual Meeting

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com